Subscribe to the BioNews newsletter for free

Login
Advanced Search

Search for
BioNews

Like the Progress Educational Trust on Facebook



 

CRISPR patent dispute ramps up with filing of court appeal

31 July 2017

By Dr Rachel Brown

Appeared in BioNews 911

The University of California has moved to appeal a decision of the US Patent Trial and Appeal Board (PTAB) over the use of CRISPR in eukaryotic cells.

This latest appeal is part of an ongoing dispute over the US patent for CRISPR/Cas9 between the University of California (UC), and the University of Vienna and Professor Emmanuelle Charpentier, against both the Broad Institute of MIT and Harvard University (Broad/MIT) regarding who has the right to a patent on the eukaryotic application of CRISPR/Cas9 technology.

'Ultimately, we expect to establish definitively that the team led by Jennifer Doudna and Emmanuelle Charpentier was the first to engineer CRISPR/Cas9 for use in all cell types including eukaryotic cells,' stated Edward Penhoet, a special adviser on CRISPR to UC.

In 2012, researchers at UC - including Professor Jennifer Doudna and Professor Emmanuelle Charpentier – first filed a patent for their discovery of CRISPR/Cas9 and its ability to edit purified DNA in vitro. Later in 2012, a team of researchers at the Broad Institute used CRISPR/Cas9 to edit the genome of eukaryotic cells, and therefore filed for a patent based on this use.

In 2014, the US Patent and Trademark Office (USPTO) granted the patent for use in eukaryotic cells to the Broad/MIT group. Despite the UC team filing their patent claim first, the Broad group asked for 'accelerated examination' and so their application was considered first.

As a result, UC Berkeley asked for an 'interference proceeding' to reassess and determine who was the first to invent the genome editing tool.

However, in February 2017, the PTAB again ruled that the Broad/MIT group could keep its patents on using CRISPR/Cas9 in eukaryotic cells, stating that there is no interference between the two groups' patent claims – that is, the one issued to the Broad/MIT group is sufficiently different from that filed by the UC team.

The UC team are now appealing this decision, stating that the work initially performed by Professor Doudna and Professor Charpentier – although it involved characterising a purified enzyme in a test tube – provided obvious evidence that genome editing could be made to work in living mammalian cells. Thus they contend that the patent held by the Broad/MIT for this application is not novel.

The UC brief – which was issued on 25 July this year – also states that the PTAB 'ignored key evidence' and 'made multiple errors' when assessing whether CRISPR/Cas9 genome editing in eukaryotes was an obvious extension of the UC invention.

However, Jacob Sherkow, an intellectual property attorney at the New York Law School has cautioned that the UC group's brief 'overplays these mistakes relative to the PTAB's analysis.' He has added that 'while there are some interesting chestnuts in its brief - such as UC pointing out that the PTAB virtually ignored some important patents pending at the time the Broad patent was filed – I don't think that's going to be enough to win the day for UC.'

This brief will be heard by the US Court of Appeals for the Federal Circuit on 25 October 2017.

SOURCES & REFERENCES
Science | 26 July 2017
 
Broad Institute | 26 July 2017
 
The Scientist | 26 July 2017
 
UC Berkeley | 26 July 2017
 

RELATED ARTICLES FROM THE BIONEWS ARCHIVE

30 October 2017 - by Jennifer Willows 
The Broad Institute has filed arguments ahead of the upcoming CRISPR patent appeal hearing...
14 August 2017 - by Ryan Ross 
German-based company MilliporeSigma has announced that the European Patent Office intends to approve its CRISPR patent for use in eukaryotic cells...

17 July 2017 - by Kulraj Singh Bhangra 
The Broad Institute of Massachusetts Institute of Technology and Harvard will take part in an initiative to simplify licensing CRISPR genome editing technology to other organisations and institutions...
03 April 2017 - by Jennifer Willows 
The European Patent Office has declared that it intends to grant a broad patent for the use of CRISPR technologies to the University of California, the University of Vienna and Dr Emmanuelle Charpentier of the Max-Planck Institute in Berlin...
20 February 2017 - by Ryan Ross 
The US Patent and Trademark Office has upheld the right of the Broad Institute of MIT and Harvard to the genome-editing tool CRISPR/Cas9...
12 December 2016 - by Antony Blackburn-Starza 
Oral arguments from lawyers acting for the Broad Institute and the University of California, Berkeley, in the high-profile CRISPR/Cas9 patent dispute have been heard in Virginia...
18 January 2016 - by Antony Blackburn-Starza 
The CRISPR 'patent wars' have now officially kicked off in the USA, with formal proceedings to determine who controls key patents over the revolutionary genome-editing technology...

HAVE YOUR SAY
Be the first to have your say.

You need to or  to add comments.

By posting a comment you agree to abide by the BioNews terms and conditions


- click here to enquire about using this story.

Published by the Progress Educational Trust

CROSSING FRONTIERS

Public Conference
London
8 December 2017

Speakers include

Professor Azim Surani

Professor Magdalena Zernicka-Goetz

Professor Robin Lovell-Badge

Sally Cheshire

Professor Guido Pennings

Katherine Littler

Professor Allan Pacey

Dr Sue Avery

Professor Richard Anderson

Dr Elizabeth Garner

Dr Andy Greenfield

Dr Anna Smajdor

Dr Henry Malter

Vivienne Parry

Dr Helen O'Neill

Dr César Palacios-González

Philippa Taylor

Fiona Fox

Sarah Norcross

Sandy Starr


BOOK HERE

Good Fundraising Code

Become a Friend of PET HERE and give the Progress Educational Trust a regular donation